Lambregts M Mc, Hendriks B Jc, Sijbom M, Sigaloff K, Nieuwhof C, de Boer M Gj
Leids Universitair Medisch Centrum.
Amsterdam UMC, locatie VUmc.
Ned Tijdschr Geneeskd. 2020 May 7;164:D4253.
Penicillin allergy is commonly reported and often influences selection of antimicrobial treatment. Due to concerns about cross-allergic reactions, other beta-lactams - particularly cephalosporins - may also be avoided. This too often results in less effective treatment, more side effects and overconsumption of reserve antimicrobial agents. Most patients (> 90%) with a penicillin allergy label are not truly allergic, i.e., they do not have an 'immediate type' (IgE-mediated) allergy when tested. Based on current data, even in patients with a true penicillin allergy, the risk of severe cross-allergic reactions to cephalosporins is very low. Clinicians tend to overestimate this risk: this dilemma can be resolved with a systematic appraisal of risk probabilities. The limited risk of a true penicillin allergy being present and the subsequent low risk of a cross-allergic reaction to cephalosporins generally outweighs the disadvantages of selecting an alternative (non-beta-lactam) antimicrobial regimen.
青霉素过敏的报告很常见,且常常影响抗菌治疗的选择。由于担心交叉过敏反应,其他β-内酰胺类药物——尤其是头孢菌素——也可能被避免使用。这常常导致治疗效果不佳、副作用增多以及储备抗菌药物的过度使用。大多数被贴上青霉素过敏标签的患者(>90%)并非真正过敏,即检测时他们没有“速发型”(IgE介导)过敏反应。根据目前的数据,即使是真正对青霉素过敏的患者,对头孢菌素发生严重交叉过敏反应的风险也非常低。临床医生往往高估了这种风险:通过系统评估风险概率可以解决这一困境。存在真正青霉素过敏的有限风险以及随后对头孢菌素发生交叉过敏反应的低风险,通常超过了选择替代(非β-内酰胺)抗菌治疗方案带来的弊端。